Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524195 · ClinicalTrials.gov registry record · Phase 1
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04524195 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 4 participants.
The verdict
NCT04524195, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).
Interventions
- DRUG [18F]F-AraG Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524195
The ClinicalTrials.gov registry entry for NCT04524195 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]F-AraG Injection is the first listed.
NCT04524195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524195 about?
NCT04524195 is a clinical study titled "PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)". This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in ...
What is the current status of trial NCT04524195?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-02-01. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT04524195?
The interventions under investigation include: [18F]F-AraG Injection (DRUG).
Who is sponsoring clinical trial NCT04524195?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.